Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.
Publication
, Journal Article
Salah, HM; Al'Aref, SJ; Khan, MS; Al-Hawwas, M; Vallurupalli, S; Mehta, JL; Mounsey, JP; Greene, SJ; McGuire, DK; Lopes, RD; Fudim, M
Published in: Am Heart J
March 2021
In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2021
Volume
233
Start / End Page
86 / 91
Location
United States
Related Subject Headings
- Sodium-Glucose Transporter 2 Inhibitors
- Sodium-Glucose Transporter 1
- Randomized Controlled Trials as Topic
- Kidney Diseases
- Kidney
- Humans
- Hospitalization
- Glycosides
- Glucosides
- Glomerular Filtration Rate
Citation
APA
Chicago
ICMJE
MLA
NLM
Salah, H. M., Al’Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., … Fudim, M. (2021). Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J, 233, 86–91. https://doi.org/10.1016/j.ahj.2020.12.007
Salah, Husam M., Subhi J. Al’Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, J Paul Mounsey, et al. “Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.” Am Heart J 233 (March 2021): 86–91. https://doi.org/10.1016/j.ahj.2020.12.007.
Salah HM, Al’Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, et al. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J. 2021 Mar;233:86–91.
Salah, Husam M., et al. “Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.” Am Heart J, vol. 233, Mar. 2021, pp. 86–91. Pubmed, doi:10.1016/j.ahj.2020.12.007.
Salah HM, Al’Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. Am Heart J. 2021 Mar;233:86–91.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2021
Volume
233
Start / End Page
86 / 91
Location
United States
Related Subject Headings
- Sodium-Glucose Transporter 2 Inhibitors
- Sodium-Glucose Transporter 1
- Randomized Controlled Trials as Topic
- Kidney Diseases
- Kidney
- Humans
- Hospitalization
- Glycosides
- Glucosides
- Glomerular Filtration Rate